ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Adiponectin Assists Thrombopoietic Agents in ITP Treatment by Enhancing Myosin-9/Rab6A-Mediated Trafficking of c-Mpl in MKs.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Single-Cell Transcriptomic Profiling Identifies B Cell-Intrinsic Dysregulation of Sphingolipid Biosynthesis and Could Be Improved by Inhibiting UGCG in Primary Immune Thrombocytopenia.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Adiponectin Assists Thrombopoietic Agents in ITP Treatment by Enhancing Myosin-9/Rab6A-Mediated Trafficking of c-Mpl in MKs.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by accelerated platelet destruction and defective platelet production. The thrombopoietin (TPO)-activated c-Mpl signaling pathway has been proven to promote megakaryocyte differentiation and platelet production and thus has significant value in the clinical treatment of ITP. However, individual differences and unsustainable responses limit the clinical application of c-Mpl agonists. The cell membrane distribution of c-Mpl is crucial for the cell response to c-Mpl agonists. In the present study, this is observed that the distribution of c-Mpl on the megakaryocyte membrane is significantly reduced in ITP patients. The reduction is more severe in refractory patients. Then, this is verified that the membrane trafficking of c-Mpl is mediated by the Myosin-9/Rab6A complex, and demonstrates that the stability of this complex depends on Rab6A-GTPase. Furthermore, this is found that adiponectin promotes the membrane localization of c-Mpl by increasing the expression of Rab6A GEFs. Finally, this is revealed that adiponectin can assist thrombopoietic agents in the treatment of ITP mice. The results clarify the c-Mpl distribution defects in the cell membrane and the corresponding c-Mpl membrane transport mechanisms in megakaryocytes of ITP, providing new insights to improve the clinical efficacy of thrombopoietic agents for ITP patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.